The Race for China's First ASO Drug: Who Will Take the Lead?

In the world of antisense oligonucleotide (ASO) drugs, China is eagerly awaiting the development of its first domestically produced ASO medication. While ASO drugs have been successfully approved and marketed globally, with some blockbuster drugs generating billions of dollars in annual sales, Chinese pharmaceutical companies have yet to receive regulatory approval for their own ASO therapies. This article explores the characteristics of ASO drugs, their market performance, and the race among Chinese pharmaceutical companies to develop and launch the country's first ASO medication.

ASO Drugs: Characteristics and Market Performance:

ASOs are chemically synthesized single-stranded nucleotide molecules, typically consisting of short sequences of 13-30 nucleotides. These sequences, designed to be complementary to target gene sequences, bind to specific RNA sequences through Watson-Crick base pairing. Through careful design guided by bioinformatics, ASOs exhibit high specificity in targeting RNA, enabling gene-specific therapeutic interventions. The first ASO drug approved for disease treatment, Fomivirsen, was launched in 1998. However, it faced strong competition from other antiretroviral drugs and was subsequently withdrawn from the European and US markets. Despite this setback, subsequent ASO drugs such as Defibrotide and Nusinersen have demonstrated market success, with Nusinersen achieving annual sales exceeding $2 billion.

The Global ASO Market:

Since the introduction of ASO drugs in the 1990s, a total of 12 ASO therapies have been approved for commercialization. The market for ASO drugs experienced a significant surge in approvals after 2013, with 11 ASO drugs launched within an 11-year period. These drugs primarily target genetic diseases, including Duchenne muscular dystrophy and other hereditary disorders. Notable companies leading ASO drug development include Ionis, Sarepta Therapeutics, Akcea Therapeutics, and Nippon Shinyaku, with Ionis being a pioneer in the field, having developed and launched six ASO drugs.

The Quest for China's First ASO Drug:

While China has yet to see the approval of a domestically developed ASO drug, several companies have embarked on ASO drug development through in-house research or licensing agreements. Some companies have chosen to collaborate with international partners, particularly those from the United States. One example is CT-102, a novel ASO drug for liver cancer jointly developed by Hangzhou Tianlong Pharmaceutical Co., Ltd., and the Academy of Military Medical Sciences. This collaboration represents a step forward in China's pursuit of its first ASO drug.

Challenges and Opportunities:

The development of ASO drugs poses both challenges and opportunities for Chinese pharmaceutical companies. Apart from the scientific and technical complexities involved in ASO drug development, high drug prices remain a significant concern. ASO drugs, including Nusinersen, have faced scrutiny due to their initially exorbitant costs. However, price reductions have facilitated broader access to these medications in China, expanding their application and influence.

China's pharmaceutical industry is poised to join the global ASO drug market with the development of its first domestically produced ASO medication. While international players have dominated the field, Chinese companies are striving to make their mark and contribute to the advancement of ASO therapies. With the potential to address unmet medical needs and improve patient outcomes, the race for China's first ASO drug promises to be a significant milestone in the country's pharmaceutical landscape.